Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders

Autores
Navarro, Daniela; Gasparyan, Ani; Navarrete, Francisco; Torregrosa, Abraham B.; Rubio, Gabriel; Marín Mayor, Marta; Acosta, Gabriela Beatriz; Garcia Gutiérrez, Maria Salud; Manzanares, Jorge
Año de publicación
2022
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The therapeutic benefits of the current medications for patients with psychiatric disorders contrast with a great variety of adverse effects. The endocannabinoid system (ECS) components have gained high interest as potential new targets for treating psychiatry diseases because of their neuromodulator role, which is essential to understanding the regulation of many brain functions. This article reviewed the molecular alterations in ECS occurring in different psychiatric conditions. The methods used to identify alterations in the ECS were also described. We used a translational approach. The animal models reproducing some behavioral and/or neurochemical aspects of psychiatric disorders and the molecular alterations in clinical studies in post-mortem brain tissue or peripheral tissues were analyzed. This article reviewed the most relevant ECS changes in prevalent psychiatric diseases such as mood disorders, schizophrenia, autism, attentional deficit, eating disorders (ED), and addiction. The review concludes that clinical research studies are urgently needed for two different purposes: (1) To identify alterations of the ECS components potentially useful as new biomarkers relating to a specific disease or condition, and (2) to design new therapeutic targets based on the specific alterations found to improve the pharmacological treatment in psychiatry.
Fil: Navarro, Daniela. Universidad Miguel Hernandez del Elche; España
Fil: Gasparyan, Ani. Universidad Miguel Hernandez del Elche; España
Fil: Navarrete, Francisco. Universidad Miguel Hernandez del Elche; España
Fil: Torregrosa, Abraham B.. Universidad Miguel Hernandez del Elche; España
Fil: Rubio, Gabriel. Hospital Universitario 12 de Octubre; España
Fil: Marín Mayor, Marta. Hospital Universitario 12 de Octubre; España
Fil: Acosta, Gabriela Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Neurociencia Cognitiva. Fundación Favaloro. Instituto de Neurociencia Cognitiva; Argentina
Fil: Garcia Gutiérrez, Maria Salud. Universidad Miguel Hernandez del Elche; España
Fil: Manzanares, Jorge. Universidad Miguel Hernandez del Elche; España
Materia
ENDOCANNABINOID SYSTEM
METHOD
MOLECULAR ALTERATION
PSYCHIATRIC DISORDERS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/211453

id CONICETDig_139eeb994da24908debef3577f7d037c
oai_identifier_str oai:ri.conicet.gov.ar:11336/211453
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Molecular Alterations of the Endocannabinoid System in Psychiatric DisordersNavarro, DanielaGasparyan, AniNavarrete, FranciscoTorregrosa, Abraham B.Rubio, GabrielMarín Mayor, MartaAcosta, Gabriela BeatrizGarcia Gutiérrez, Maria SaludManzanares, JorgeENDOCANNABINOID SYSTEMMETHODMOLECULAR ALTERATIONPSYCHIATRIC DISORDERShttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3The therapeutic benefits of the current medications for patients with psychiatric disorders contrast with a great variety of adverse effects. The endocannabinoid system (ECS) components have gained high interest as potential new targets for treating psychiatry diseases because of their neuromodulator role, which is essential to understanding the regulation of many brain functions. This article reviewed the molecular alterations in ECS occurring in different psychiatric conditions. The methods used to identify alterations in the ECS were also described. We used a translational approach. The animal models reproducing some behavioral and/or neurochemical aspects of psychiatric disorders and the molecular alterations in clinical studies in post-mortem brain tissue or peripheral tissues were analyzed. This article reviewed the most relevant ECS changes in prevalent psychiatric diseases such as mood disorders, schizophrenia, autism, attentional deficit, eating disorders (ED), and addiction. The review concludes that clinical research studies are urgently needed for two different purposes: (1) To identify alterations of the ECS components potentially useful as new biomarkers relating to a specific disease or condition, and (2) to design new therapeutic targets based on the specific alterations found to improve the pharmacological treatment in psychiatry.Fil: Navarro, Daniela. Universidad Miguel Hernandez del Elche; EspañaFil: Gasparyan, Ani. Universidad Miguel Hernandez del Elche; EspañaFil: Navarrete, Francisco. Universidad Miguel Hernandez del Elche; EspañaFil: Torregrosa, Abraham B.. Universidad Miguel Hernandez del Elche; EspañaFil: Rubio, Gabriel. Hospital Universitario 12 de Octubre; EspañaFil: Marín Mayor, Marta. Hospital Universitario 12 de Octubre; EspañaFil: Acosta, Gabriela Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Neurociencia Cognitiva. Fundación Favaloro. Instituto de Neurociencia Cognitiva; ArgentinaFil: Garcia Gutiérrez, Maria Salud. Universidad Miguel Hernandez del Elche; EspañaFil: Manzanares, Jorge. Universidad Miguel Hernandez del Elche; EspañaMolecular Diversity Preservation International2022-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/211453Navarro, Daniela; Gasparyan, Ani; Navarrete, Francisco; Torregrosa, Abraham B.; Rubio, Gabriel; et al.; Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders; Molecular Diversity Preservation International; International Journal of Molecular Sciences; 23; 9; 4-2022; 1-661422-0067CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/1422-0067/23/9/4764info:eu-repo/semantics/altIdentifier/doi/10.3390/ijms23094764info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:50:58Zoai:ri.conicet.gov.ar:11336/211453instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:50:58.953CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders
title Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders
spellingShingle Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders
Navarro, Daniela
ENDOCANNABINOID SYSTEM
METHOD
MOLECULAR ALTERATION
PSYCHIATRIC DISORDERS
title_short Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders
title_full Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders
title_fullStr Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders
title_full_unstemmed Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders
title_sort Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders
dc.creator.none.fl_str_mv Navarro, Daniela
Gasparyan, Ani
Navarrete, Francisco
Torregrosa, Abraham B.
Rubio, Gabriel
Marín Mayor, Marta
Acosta, Gabriela Beatriz
Garcia Gutiérrez, Maria Salud
Manzanares, Jorge
author Navarro, Daniela
author_facet Navarro, Daniela
Gasparyan, Ani
Navarrete, Francisco
Torregrosa, Abraham B.
Rubio, Gabriel
Marín Mayor, Marta
Acosta, Gabriela Beatriz
Garcia Gutiérrez, Maria Salud
Manzanares, Jorge
author_role author
author2 Gasparyan, Ani
Navarrete, Francisco
Torregrosa, Abraham B.
Rubio, Gabriel
Marín Mayor, Marta
Acosta, Gabriela Beatriz
Garcia Gutiérrez, Maria Salud
Manzanares, Jorge
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv ENDOCANNABINOID SYSTEM
METHOD
MOLECULAR ALTERATION
PSYCHIATRIC DISORDERS
topic ENDOCANNABINOID SYSTEM
METHOD
MOLECULAR ALTERATION
PSYCHIATRIC DISORDERS
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv The therapeutic benefits of the current medications for patients with psychiatric disorders contrast with a great variety of adverse effects. The endocannabinoid system (ECS) components have gained high interest as potential new targets for treating psychiatry diseases because of their neuromodulator role, which is essential to understanding the regulation of many brain functions. This article reviewed the molecular alterations in ECS occurring in different psychiatric conditions. The methods used to identify alterations in the ECS were also described. We used a translational approach. The animal models reproducing some behavioral and/or neurochemical aspects of psychiatric disorders and the molecular alterations in clinical studies in post-mortem brain tissue or peripheral tissues were analyzed. This article reviewed the most relevant ECS changes in prevalent psychiatric diseases such as mood disorders, schizophrenia, autism, attentional deficit, eating disorders (ED), and addiction. The review concludes that clinical research studies are urgently needed for two different purposes: (1) To identify alterations of the ECS components potentially useful as new biomarkers relating to a specific disease or condition, and (2) to design new therapeutic targets based on the specific alterations found to improve the pharmacological treatment in psychiatry.
Fil: Navarro, Daniela. Universidad Miguel Hernandez del Elche; España
Fil: Gasparyan, Ani. Universidad Miguel Hernandez del Elche; España
Fil: Navarrete, Francisco. Universidad Miguel Hernandez del Elche; España
Fil: Torregrosa, Abraham B.. Universidad Miguel Hernandez del Elche; España
Fil: Rubio, Gabriel. Hospital Universitario 12 de Octubre; España
Fil: Marín Mayor, Marta. Hospital Universitario 12 de Octubre; España
Fil: Acosta, Gabriela Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Neurociencia Cognitiva. Fundación Favaloro. Instituto de Neurociencia Cognitiva; Argentina
Fil: Garcia Gutiérrez, Maria Salud. Universidad Miguel Hernandez del Elche; España
Fil: Manzanares, Jorge. Universidad Miguel Hernandez del Elche; España
description The therapeutic benefits of the current medications for patients with psychiatric disorders contrast with a great variety of adverse effects. The endocannabinoid system (ECS) components have gained high interest as potential new targets for treating psychiatry diseases because of their neuromodulator role, which is essential to understanding the regulation of many brain functions. This article reviewed the molecular alterations in ECS occurring in different psychiatric conditions. The methods used to identify alterations in the ECS were also described. We used a translational approach. The animal models reproducing some behavioral and/or neurochemical aspects of psychiatric disorders and the molecular alterations in clinical studies in post-mortem brain tissue or peripheral tissues were analyzed. This article reviewed the most relevant ECS changes in prevalent psychiatric diseases such as mood disorders, schizophrenia, autism, attentional deficit, eating disorders (ED), and addiction. The review concludes that clinical research studies are urgently needed for two different purposes: (1) To identify alterations of the ECS components potentially useful as new biomarkers relating to a specific disease or condition, and (2) to design new therapeutic targets based on the specific alterations found to improve the pharmacological treatment in psychiatry.
publishDate 2022
dc.date.none.fl_str_mv 2022-04
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/211453
Navarro, Daniela; Gasparyan, Ani; Navarrete, Francisco; Torregrosa, Abraham B.; Rubio, Gabriel; et al.; Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders; Molecular Diversity Preservation International; International Journal of Molecular Sciences; 23; 9; 4-2022; 1-66
1422-0067
CONICET Digital
CONICET
url http://hdl.handle.net/11336/211453
identifier_str_mv Navarro, Daniela; Gasparyan, Ani; Navarrete, Francisco; Torregrosa, Abraham B.; Rubio, Gabriel; et al.; Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders; Molecular Diversity Preservation International; International Journal of Molecular Sciences; 23; 9; 4-2022; 1-66
1422-0067
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.mdpi.com/1422-0067/23/9/4764
info:eu-repo/semantics/altIdentifier/doi/10.3390/ijms23094764
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Molecular Diversity Preservation International
publisher.none.fl_str_mv Molecular Diversity Preservation International
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269064982953984
score 13.13397